Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Opiant Pharmaceuticals Inc
(NQ:
OPNT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 1, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Opiant Pharmaceuticals Inc
< Previous
1
2
3
Next >
110 Biggest Movers From Friday
May 16, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Via
Benzinga
Why Opiant Pharmaceuticals Shares Are Soaring Today
April 28, 2022
Via
Benzinga
Earnings Scheduled For November 11, 2021
November 11, 2021
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape...
Via
Benzinga
Earnings Scheduled For August 11, 2022
August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Opiant Pharma Secures Additional BARDA Funding For Opioid Overdose Treatment
August 09, 2022
Via
Benzinga
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
June 06, 2022
Via
AB Newswire
Stocks That Hit 52-Week Lows On Friday
May 13, 2022
On Friday, 153 companies set new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 11, 2022
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
99 Biggest Movers From Yesterday
May 12, 2022
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.
Via
Benzinga
Earnings Scheduled For May 10, 2022
May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Via
Benzinga
A Preview Of Opiant Pharmaceuticals's Earnings
May 09, 2022
Opiant Pharmaceuticals (NASDAQ:OPNT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
70 Biggest Movers From Friday
May 02, 2022
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 29, 2022
Via
Benzinga
48 Stocks Moving In Friday's Mid-Day Session
April 29, 2022
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
April 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
President Biden To Outline Strategy To Tackle Drug Addiction, Overdose: Reuters
April 21, 2022
Via
Benzinga
Looking Into Opiant Pharmaceuticals's Return On Capital Employed
March 17, 2022
According to Benzinga Pro, during Q4, Opiant Pharmaceuticals (NASDAQ:OPNT) earned $752.33 thousand, a 77.98% increase from the preceding quarter. Opiant Pharmaceuticals's sales...
Via
Benzinga
Opiant Pharmaceuticals: Q4 Earnings Insights
March 15, 2022
Opiant Pharmaceuticals (NASDAQ:OPNT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Opiant Pharmaceuticals's Earnings Outlook
March 14, 2022
Opiant Pharmaceuticals (NASDAQ:OPNT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement....
Via
Benzinga
Opiant's Multi-Dose Nasal Nalmefene Shows Safety, Tolerability In Opioid Overdose
February 10, 2022
Opiant Pharmaceuticals Inc (NASDAQ: OPNT)
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
January 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,...
Via
Benzinga
Earnings Scheduled For March 15, 2022
March 15, 2022
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi...
Via
Benzinga
Under BARDA Contract, Opiant Pharma Secures Additional Funding Of $2M For Opioid Overdose Program
January 25, 2022
The Biomedical Advanced Research and Development Authority (BARDA) will provide additional funding of up to $2.2 million to support Opiant Pharmaceuticals Inc's...
Via
Benzinga
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
January 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura...
Via
Benzinga
Opiant Pharma Starts Dosing In OPNT002 Mid-Stage Study For Alcohol Use Disorder
January 21, 2022
Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder (AUD). The...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
November 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
October 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.